Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Sarah Maloney

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9333-2490; OpenAlex author ID A5001113443. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 3 papers · 2024: 1 paper · 2025: 2 papers

Papers 10

  1. Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. Co-author DOI 10.1111/eci.14341↗
  2. Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuvant chemotherapy prior to surgery. Co-author DOI 10.1111/eci.70046↗
  3. Serum and tissue metallome of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16124↗
  4. The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer. Co-author DOI 10.1007/s00432-023-05149-4↗
  5. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  6. The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as B… Co-author DOI 10.3390/jcm12051989↗
  7. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33368↗
  8. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Co-author DOI 10.1016/j.ejso.2021.04.005↗
  9. Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. Co-author DOI 10.3390/jcm10122700↗
  10. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. Co-author DOI 10.1016/j.bbagen.2020.129682↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaswinder Singh Samra · 9 shared papers, 2020–2025 · strength 1.52
  2. Anubhav Mittal · 9 shared papers, 2020–2025 · strength 1.52
  3. Sumit Sahni · 8 shared papers, 2020–2025 · strength 1.41
  4. Anthony James Gill · 8 shared papers, 2020–2025 · strength 1.32
  5. Stephen John Clarke · 5 shared papers, 2021–2025 · strength 0.82
  6. Nick Pavlakis · 5 shared papers, 2021–2025 · strength 0.82
  7. Sooin Byeon · 3 shared papers, 2024–2025 · strength 0.69
  8. David Lok Hang Chan · 3 shared papers, 2021–2025 · strength 0.50
  9. Angela S. Y. Chou · 2 shared papers, 2025 · strength 0.48
  10. Emily K. Colvin · 2 shared papers, 2023 · strength 0.35
  11. Christopher Bahdah Nahm · 3 shared papers, 2020–2021 · strength 0.34
  12. Josef Gillson · 2 shared papers, 2020–2025 · strength 0.34
  13. Malinda Itchins · 2 shared papers, 2021–2023 · strength 0.29
  14. Taymin du Toit‐Thompson · 1 shared paper, 2024 · strength 0.22
  15. James A. Toft · 1 shared paper, 2021 · strength 0.12
  16. Matthew H. G. Katz · 1 shared paper, 2023 · strength 0.12
  17. Raëf Abdallah · 1 shared paper, 2023 · strength 0.12
  18. Jin‐Young Jang · 1 shared paper, 2023 · strength 0.12
  19. Giuseppe Malleo · 1 shared paper, 2023 · strength 0.12
  20. Gregory C. Wilson · 1 shared paper, 2023 · strength 0.12
  21. Ryan K. Schmocker · 1 shared paper, 2023 · strength 0.12
  22. Jin Peng He · 1 shared paper, 2023 · strength 0.12
  23. Russell F. Palm · 1 shared paper, 2023 · strength 0.12
  24. John Bart Rose · 1 shared paper, 2023 · strength 0.12
  25. Yoo Jin Choi · 1 shared paper, 2023 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.